 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| 123456789101112» |
- | Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Journal: Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial. (Pubmed Central) - Jan 16, 2025
P3
This subgroup analysis of the ASCEND-D trial demonstrated comparable efficacy and safety of daprodustat versus darbepoetin alfa in PD patients, supporting its use in the treatment of anemia in these patients.
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Acute Kidney Injury after Cardiac Surgery Is Associated with Increased Iron Deficiency Anemia Risk () - Dec 7, 2024 - Abstract #ASH2024ASH_9735;
The increased 12-month risk of IDA and repeat cardiac surgery was mitigated with ESA treatment within 3 months with no increase in acute MI. Postoperative ESA use may protect against AKI-associated anemia without increased adverse events, representing an opportunity to improve health outcomes.
- Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Risks and Harms to Physicians Reporting Hematologic Adverse Drug Reactions (ADRs) to Health Authorities () - Dec 7, 2024 - Abstract #ASH2024ASH_9597;
ADR findings resulted in drug removal (n = 7; Vioxx, Avandia, Bextra, Celebrex, Trasylol, Phenyl propanolamine, Hydroxy-ethyl starch), revised indications (n = 2) (Procrit, Aranesp 2007, 2008, 2010)) or 10-year delay in FDA-approval (n = 1) (Fereprox)...Pharmaceutical companies paid $600,000 (Fereprox) to $5.8 billion (Vioxx) in fines and settlements.Discussion : Twelve physicians experienced severe threats and/or harms after reporting hematologic-associated ADRs to Health Authorities and/or in major publications. We suggest physicians not sign secrecy agreements that might jeopardize public safety (as currently established by almost all US medical universities) and should partner with independent drug safety monitoring boards (DSMBs) on ADR evaluations to monitor safety concerns of drugs and medical devices.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Luspatercept for the Treatment of Transfusion-Dependent Anemia in Patients with Myelodysplastic Neoplasms with del5q, Refractory/Resistant/Intolerant to Prior Treatments (QOL-ONE Phoenix) () - Dec 7, 2024 - Abstract #ASH2024ASH_8777;
One responder experienced grade 3 paresthesia, an unrelated adverse event, which resolved after one week of dose delay.Conclusion : Preliminary interim results show a positive signal of efficacy and safety of luspatercept in MDS with del5q resistant, refractory, intolerant or ineligible to other treatments. Final trial results will inform on the value of luspatercept for the benefit of TD patients.
- Avastin (bevacizumab) / Roche
Bevacizumab Results in Complete and Prolonged Cessation of Refractory Bleeding from Gastrointestinal Arteriovenous Malformations Even after Treatment Discontinuation () - Dec 7, 2024 - Abstract #ASH2024ASH_7575;
This finding has important implications in terms of treatment duration as treatment discontinuation may avoid development of complications and result in healthcare cost-savings.Conclusion : This case represents a novel use of bevacizumab for managing transfusion-dependent, refractory anemia secondary to GI angiodysplasia in patients with ESRD. Further studies are needed to establish optimal dosing schedules, and whether treatment can be discontinued safely in stable patients.
- | Epogen (epoetin alfa) / Amgen
Trial completion date: Pharmacological Countermeasures for High Altitude (clinicaltrials.gov) - Dec 4, 2024
P4, N=18, Active, not recruiting, Sponsor: United States Army Research Institute of Environmental Medicine
Further studies are needed to establish optimal dosing schedules, and whether treatment can be discontinued safely in stable patients. Trial completion date: Dec 2024 --> Mar 2025
- || Epogen (epoetin alfa) / Amgen
Review, Journal: Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments. (Pubmed Central) - Nov 21, 2024
Results from these trials will need to be interpreted and validated in LMIC settings. The focus of future research should therefore be on the development of inexpensive, accessible monotherapies and should include LMICs, where the highest burden of NESHIE exists.
- | Epogen (epoetin alfa) / Amgen
Enrollment open: EpoAid: Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients with Sepsis or Septic Shock: a Randomized Controlled Trial (clinicaltrials.gov) - Nov 13, 2024
P4, N=200, Recruiting, Sponsor: Medical University of Silesia
The focus of future research should therefore be on the development of inexpensive, accessible monotherapies and should include LMICs, where the highest burden of NESHIE exists. Not yet recruiting --> Recruiting
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5759;
P3
Conclusions : The analyses indicate superior treatment effects of luspatercept over epoetin alfa on shortening time to achieving a meaningful HRQoL improvement or delaying time to experiencing a meaningful HRQoL deterioration or RBC transfusion. These findings provide further evidence to support the use of luspatercept as a front-line treatment for patients with RBC transfusion-dependent LR-MDS.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5729;
P3
Conclusions : The findings from the COMMANDS trial demonstrated that luspatercept treatment led to a decrease in RBCT burden compared with epoetin alfa in ESA-naive pts with LR-MDS, evident by the number of RBC units transfused and RBCT visits over a 1.5-year period. When analyzed by RBCT burden category, transfusion burden was also substantially lower for luspatercept compared with epoetin alfa.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Clinical Benefits of Achieving Hemoglobin (Hb) Levels ? 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5715;
P3
Luspatercept dose escalation maintained target Hb levels without significantly increasing incidence or severity of TEAEs. Pts with lower Hb levels at baseline showed a trend requiring higher dose, supporting the clinical benefit of luspatercept dose escalation in pts with LR-MDS.
- hydroxyurea / Generic mfg.
A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD) (Hall B (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2425;
P1/2
9.0 g/dL, on stable-dose HU, and no recent transfusions, voxelotor or ESA treatment...Nearly all participants experienced a Hb response with a relatively low-to-moderate dose of EPO. Subsequent analyses will evaluate the effect of EPO therapy on transfusion burden and other clinical outcomes.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study (Ballroom 20AB (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2200;
Based on a TITE-BOIN-ET design, Epoetin alfa was administered weekly at dose concentrations ranging from 30 000UI to 60 000 UI...All patients had resistance to ESA and 7 had also received Revlimid (n=3), IDH inhibitors (n=2), Thalidomide (n=1), AZA (n=1)...Based on the results of this Phase 1 study, the dosing schedule Luspatercept 1.75 mg/kg/21d and EPO 60 000 UI/w, that balanced clinical efficacy and safety profile was selected as the RP2D. This regimen is being compared to Luspatercept 1.75 mg/kg/21d in the ongoing randomized Phase 2 study.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent (Ballroom 20AB (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2199;
P3
Progression rates to high-risk MDS and AML were low in both treatment arms. These data support luspatercept as the treatment of choice in TD ESA-naive pts with lower-risk MDS.
- | Epogen (epoetin alfa) / Amgen
Trial completion date: Pharmacological Countermeasures for High Altitude (clinicaltrials.gov) - Nov 4, 2024
P4, N=18, Active, not recruiting, Sponsor: United States Army Research Institute of Environmental Medicine
These data support luspatercept as the treatment of choice in TD ESA-naive pts with lower-risk MDS. Trial completion date: Sep 2024 --> Dec 2024
- | Epogen (epoetin alfa) / Amgen
New P4 trial: EpoAid: Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients with Sepsis or Septic Shock: a Randomized Controlled Trial (clinicaltrials.gov) - Oct 31, 2024
P4, N=200, Not yet recruiting, Sponsor: Medical University of Silesia
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal, Real-world evidence, Real-world: Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa. (Pubmed Central) - Oct 17, 2024
The effect was particularly high in the IPSS-M low and very low groups. We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients.
- |||||||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Enrollment change, Trial withdrawal, HEOR, Real-world evidence, Real-world: CA056-1083: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 9, 2024
P=N/A, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients. Not yet recruiting --> Withdrawn | N=86 --> 0
- | hydroxyurea / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: ACHiEvE-SCD: Hydroxyurea and EPO in Sickle Cell Disease (clinicaltrials.gov) - Sep 25, 2024
P1/2, N=17, Active, not recruiting, Sponsor: Julia Xu
Not yet recruiting --> Withdrawn | N=86 --> 0 Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: May 2025 --> Dec 2024
- Epogen (epoetin alfa) / Amgen
Acute Tubular Necrosis (ATN) after Hemopure in a Patient with Sickle Cell Disease (SCD) (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3348;
She was given Epogen 20,000 IU daily and was diuresed with robust urinary response (3L/24hr)...Renal side effects include hypertension attributed to heme scavenging of endothelial nitric oxide, and nephrotoxicity possibly from renal oxidative stress and vasoconstriction. This case seeks to contribute to the growing body of literature on the safety and risks associated with HBOCs.
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Treatment of Clinically Meaningful Anemia by Prescriber Type in Nondialysis-Dependent CKD Patients in the United States (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1966;
RBCT was the most common initial treatment versus ESAs which increased with longer follow-up. Treatment patterns varied by prescriber type with nephrologists prescribing ESAs most frequently.
- Epogen (epoetin alfa) / Amgen
Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1936;
P3
Treatment patterns varied by prescriber type with nephrologists prescribing ESAs most frequently. Pegmolesatide demonstrated a stronger likelihood of maintaining Hb levels within guideline-recommended ranges and potentially provided a more favorable safety profile compared to epoetin alfa.
- chlorpromazine / Generic mfg.
A RARE CASE OF CHLORPROMAZINE-INDUCED IMMUNE HEMOLYTIC ANEMIA (Convention Center Exhibit Hall: Poster Area 2) - Sep 19, 2024 - Abstract #CHEST2024CHEST_7313;
The hematologist was consulted immediately, and the patient received one dose of IV Epoetin alfa 20000 units, one dose of IV Venofer 200 mg and she was also started on IV methylprednisolone 80 mg...The patient's home medications included Chlorpromazine, Divalproex, and Fluoxetine...He was discharged to home with prednisone and divalproex...Cephalosporins, nonsteroidal anti-inflammatory agents, levofloxacin, oxaliplatin, and teicoplanin have been reported to cause IHA... Chlorpromazine is a widely used drug in psychiatry and physicians should be aware of this rare adverse event of hemolytic anemia.
- |||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New trial, HEOR, Real-world evidence, Real-world: CA056-1083: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 30, 2024
P=N/A, N=86, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Epogen (epoetin alfa) / Amgen
Iron Overload: A Case of Hidden Hemochromatosis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3556;
Patient was recommended to switch from IV iron to Epogen therapy, and discharged with outpatient follow-up, which were not pursued...While, the diagnosis of acquired hemochromatosis typically requires a TSAT > 45% alongside elevated ferritin levels, prior literature has shown these values to not be the most reliable indicator of hepatic iron stores. Chelation is typically initiated prophylactically in patients receiving over 10 units of blood, but was delayed in our patient with acquired hemochromatosis, underscoring the need for physician vigilance and timely intervention in these cases.
- ||||| Epogen (epoetin alfa) / Amgen
Trial initiation date: ENCASE: Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients (clinicaltrials.gov) - Aug 18, 2024
P3, N=280, Not yet recruiting, Sponsor: Megalabs
Chelation is typically initiated prophylactically in patients receiving over 10 units of blood, but was delayed in our patient with acquired hemochromatosis, underscoring the need for physician vigilance and timely intervention in these cases. Initiation date: Jul 2024 --> Jul 2025
- | hydroxyurea / Generic mfg.
Trial primary completion date: ACHiEvE-SCD: Hydroxyurea and EPO in Sickle Cell Disease (clinicaltrials.gov) - Aug 4, 2024
P1/2, N=15, Recruiting, Sponsor: Julia Xu
Initiation date: Jul 2024 --> Jul 2025 Trial primary completion date: Nov 2024 --> May 2025
- | Epogen (epoetin alfa) / Amgen
Journal: Evaluation of serum ferritin level and hepatitis b and hepatitis c viral infection in chronic hemodialysis patients. (Pubmed Central) - Aug 4, 2024
The study aimed to assess serum ferritin levels and their connection to Epoetin alfa resistance, along with exploring the link between hepatitis C virus, iron overload, and the prevalence of hepatitis C and B infections in chronic HD patients...Excessive blood transfusions can lead to iron overload and inhibit erythropoiesis. Maintaining HB at 110-120 g/l improves quality of life and reduces anemia-related risks.
- Epogen (epoetin alfa) / Amgen
A RARE HIT: HEPARIN-INDUCED THROMBOCYTOPENIA CAUSING PERIOPERATIVE ACUTE GRAFT OCCLUSION FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY (Convention Center Exhibit Hall: Rapid Fire Area 1A) - Jul 31, 2024 - Abstract #CHEST2024CHEST_4993;
A high degree of suspicion and surveillance is needed to diagnose and timely initiate optimal management to reduce further complications. Some studies have postulated the use of bivalirudin to prevent HIT but further research is needed to investigate this approach.
- |||||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Vafseo (vadadustat) / Akebia Therap
New P3 trial: VOICE: Vafseo Outcomes In-Center Experience (clinicaltrials.gov) - Jul 24, 2024
P3, N=2200, Not yet recruiting, Sponsor: USRC Kidney Research
- | Epogen (epoetin alfa) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Pharmacological Countermeasures for High Altitude (clinicaltrials.gov) - Jul 16, 2024
P4, N=18, Active, not recruiting, Sponsor: United States Army Research Institute of Environmental Medicine
Some studies have postulated the use of bivalirudin to prevent HIT but further research is needed to investigate this approach. Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Sep 2024 | Trial primary completion date: Aug 2022 --> Sep 2023
- || Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Clinical, Retrospective data, Journal: The effect of erythropoiesis?stimulating agents on lung cancer patients: a meta?analysis. (Pubmed Central) - Jul 5, 2024
There was no statistically significant difference between the two groups in the incidence of adverse reactions (RR 0.98, 95% CI 0.95-1.00, P?=?0.10). In conclusion, ESAs does not increase the mortality of lung cancer patients or may reduce the risk of death, and can reduce the need for blood transfusion, although ESA can increase the incidence of thrombotic vascular adverse events.Registration PROSPERO CRD42023463582.
- ||| AND017 / Hangzhou Andao Pharma
Trial completion, Enrollment change: A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis (clinicaltrials.gov) - Jun 27, 2024
P2, N=175, Completed, Sponsor: Kind Pharmaceuticals LLC
In conclusion, ESAs does not increase the mortality of lung cancer patients or may reduce the risk of death, and can reduce the need for blood transfusion, although ESA can increase the incidence of thrombotic vascular adverse events.Registration PROSPERO CRD42023463582. Active, not recruiting --> Completed | N=120 --> 175
- | Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal: Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis. (Pubmed Central) - Jun 16, 2024
Compared with short-acting ESAs, long-acting ESAs were associated with a lower risk of all-cause mortality, with no difference in the risk of MACE. Future studies with a longer follow-up are needed to confirm these findings.
- | Epogen (epoetin alfa) / Amgen
Trial completion, Trial completion date, Trial primary completion date, Adverse events: PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns (clinicaltrials.gov) - Jun 4, 2024
P3, N=313, Completed, Sponsor: University of Sydney
Future studies with a longer follow-up are needed to confirm these findings. Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023
- | Epogen (epoetin alfa) / Amgen
Journal: Assessing EPO stability in urine and comparing recombinant EPO detectability in matched urine, venous serum, and capillary serum following a controlled epoetin alfa administration. (Pubmed Central) - May 24, 2024
In most cases, rEPO was detectable for at least 168?h post-administration. Noting greater stability in blood compared with urine, it is recommended that anti-doping authorities utilize this novel capillary serum collection technology to improve overall ERA detectability in doping control samples.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA) (Hall A; Poster Bd #: 124) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1201;
P3
Noting greater stability in blood compared with urine, it is recommended that anti-doping authorities utilize this novel capillary serum collection technology to improve overall ERA detectability in doping control samples. Pts were randomized 1:1 to subcutaneous administration of luspatercept (1.0
- |||||||||| Epogen (epoetin alfa) / Amgen
New P3 trial: ENCASE: Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients (clinicaltrials.gov) - Apr 7, 2024
P3, N=280, Not yet recruiting, Sponsor: Megalabs
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal: Short versus long-acting erythropoiesis-stimulating agents for anemia management in Egyptian hemodialysis patients. (Pubmed Central) - Apr 3, 2024
P
Pts were randomized 1:1 to subcutaneous administration of luspatercept (1.0 In hemodialysis Egyptian patients, Aranesp with extended dosing intervals proved to be more effective in achieving target Hb with comparable adverse effect profiles, a substantial cost-saving strategy, and offered time-saving advantages for medical staff workload compared to Eprex.
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Journal: Daprodustat (Jesduvroq) for anemia of chronic kidney disease. (Pubmed Central) - Mar 2, 2024
In hemodialysis Egyptian patients, Aranesp with extended dosing intervals proved to be more effective in achieving target Hb with comparable adverse effect profiles, a substantial cost-saving strategy, and offered time-saving advantages for medical staff workload compared to Eprex. No abstract available
- || AND017 / Hangzhou Andao Pharma
Enrollment closed: A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis (clinicaltrials.gov) - Feb 22, 2024
P2, N=120, Active, not recruiting, Sponsor: Kind Pharmaceuticals LLC
No abstract available Recruiting --> Active, not recruiting
- | Epogen (epoetin alfa) / Amgen
Journal: Iron and erythropoietin to heal and recover after intensive care (ITHRIVE): A pilot randomised clinical trial. (Pubmed Central) - Jan 18, 2024
Recruiting --> Active, not recruiting A single dose of IV ferric carboxymaltose and Epoetin alfa (active group)
- Epogen (epoetin alfa) / Amgen
Supporting a Pediatric Jehovah's Witness Patient on a Ventricular Assist Device to Transplantation (Board #40; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1768;
Postoperatively, in the ICU, she experienced significant bleeding (hemoglobin drop from 12.9 to 5.7 g/dL) with hemodynamic compromise requiring chest exploration and tranexamic acid...To promote count recovery, iron supplementation and Epoetin alfa were started...Stimulation of erythropoiesis pre-operatively along with aggressive blood sparing intra-operative strategies may entirely eliminate the need for transfusions. Generalized adoption of these blood sparing techniques would likely be beneficial to all patients undergoing complex cardiac surgeries.
- | Epogen (epoetin alfa) / Amgen
Journal: Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States. (Pubmed Central) - Dec 18, 2023
Hemoglobin and ESA dosing distributions are stable, with epoetin alfa dosing below the low-target arm of the NHCT. Persistently low hemoglobin occurs infrequently and may reflect iron depletion.
- || Epogen (epoetin alfa) / Amgen
Clinical, Journal: Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. (Pubmed Central) - Nov 13, 2023
P3
Monthly subcutaneously injection of pegmolesatide was as effective and safe as conventional epoetin alfa administrated one to three times a week in treating anemia in Chinese dialysis patients. The study was supported by Hansoh Medical Development Group.
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Na (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6044;
Luspatercept was also found to be well-tolerated by the majority of patients. All of these PRO findings further support the benefits of luspatercept in ESA-na
- Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims D... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2890;
Achievement of TI was associated with improved survival, suggesting that RBC-TD is a modifiable predictor of clinical outcomes in LR-MDS. Despite the currently available therapies, RBC-TD after any line of therapy is associated with poorer outcomes.
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis ... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2270;
P3
Additionally, decreased or static levels of NT-proBNP with luspatercept suggest a positive effect in mitigating cardiac damage. These novel insights obtained from analysis of a large controlled clinical trial mechanistically differentiate the superior clinical benefit of luspatercept from EA in treating anemia due to MDS.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2244;
P2
These novel insights obtained from analysis of a large controlled clinical trial mechanistically differentiate the superior clinical benefit of luspatercept from EA in treating anemia due to MDS. Methods Pts were enrolled into 4 cohorts based on transfusion dependence (TD) and stable ruxolitinib (RUX) treatment
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (L... (Marriott Marquis - Pacific Ballroom) - Nov 3, 2023 - Abstract #ASH2023ASH_1213;
P3
Luspatercept safety results were consistent with previous MDS studies. These data show that luspatercept could represent a new standard of care for pts with TD LR-MDS.